Personal Investment Vitae

Home > Personal Investment Vitae

AYA Personal Investment Vitae as of July 2026
Laura Hermes @Laura Hermes
Platinum member since January 2017

Location: United States

Gender: Female

Asset investment style: Qualitative fundamental analysis

Market capitalization:

$8,573,084talents

Virtual portfolio value:

$5,411,513talents

Net overall return per annum:

19.46%

AYA current rank order:

#3

Asset investment philosophy:
Laura Hermes trades U.S. stocks with the top #51 to #500 positive alpha signals.

Top 10 profitable stock transactions since January 2020Strategy

Symbol Company Buy Sell Share Volume Return (%) Profit ($)
RMBL RumbleOn Inc. Class B Common Stock $0.36 $7.95 51,225 +2,108.33% $388,798
HAO Haoxi Health Technology Limited Class A Ordinary Shares $0.15 $2.50 86,720 +1,566.67% $203,792
LSCC Lattice Semiconductor Corporation Common Stock $6.97 $48.04 4,471 +589.24% $183,624
SXTP 60 Degrees Pharmaceuticals Inc. Common Stock $0.15 $1.34 119,533 +793.33% $142,244
NTZ Natuzzi S.p.A. $2.21 $11.92 14,103 +439.37% $136,940
VATE INNOVATE Corp. Common Stock $0.53 $4.14 33,830 +681.13% $122,126
BQ Boqii Holding Limited American Depositary Shares representing Class A Ordinary Shares $0.36 $3.36 36,133 +833.33% $108,399
BQ Boqii Holding Limited Class A Ordinary Shares $0.36 $3.36 36,133 +833.33% $108,399
SSNT SilverSun Technologies Inc. Common Stock $18.59 $130.48 801 +601.88% $89,624
LGVN Longeveron Inc. Class A Common Stock $3.45 $26.25 2,526 +660.87% $57,593
Sum $1,541,539

Top 20 influencers

#1 - #5 #6 - #10 #11 - #15 #15 - #20
@alin
@John Fourier
@Andy Yeh Alpha
@Chanel Holden

Blog+More

Precautionary-motive and agency reasons for corporate cash management

Monica McNeil

2022-10-05 08:24:00 Wednesday ET

Precautionary-motive and agency reasons for corporate cash management

Precautionary-motive and agency reasons for corporate cash management Bates, Kahle, and Stulz (JF 2009) empirically find that public firms have doubled t

+See More

Reuters polls show that most Americans blame President Trump for the recent U.S. government shutdown.

Olivia London

2019-01-05 11:39:00 Saturday ET

Reuters polls show that most Americans blame President Trump for the recent U.S. government shutdown.

Reuters polls show that most Americans blame President Trump for the recent U.S. government shutdown. President Trump remains adamant about having to shut d

+See More

Most major economies grow with great synchronicity several years after the global financial crisis.

John Fourier

2018-01-19 11:32:00 Friday ET

Most major economies grow with great synchronicity several years after the global financial crisis.

Most major economies grow with great synchronicity several years after the global financial crisis. These economies experience high stock market valuation,

+See More

Michael Sandel analyzes what money cannot buy in stark contrast to the free market ideology of capitalism.

Daisy Harvey

2023-06-21 12:32:00 Wednesday ET

Michael Sandel analyzes what money cannot buy in stark contrast to the free market ideology of capitalism.

Michael Sandel analyzes what money cannot buy in stark contrast to the free market ideology of capitalism. Michael Sandel (2013)   What money

+See More

The Economist suggests that the world has learned few lessons of the global financial crisis from 2008 to 2009.

Becky Berkman

2018-09-07 07:33:00 Friday ET

The Economist suggests that the world has learned few lessons of the global financial crisis from 2008 to 2009.

The Economist re-evaluates the realistic scenario that the world has learned few lessons of the global financial crisis from 2008 to 2009 over the past deca

+See More

The global market for GLP-1 weight-loss medications can grow substantially to benefit more than 1 billion people worldwide by 2030.

Monica McNeil

2025-10-31 12:26:00 Friday ET

The global market for GLP-1 weight-loss medications can grow substantially to benefit more than 1 billion people worldwide by 2030.

With respect to wider weight loss treatment and obesity treatment, the global market for GLP-1 medications now grows substantially to benefit more than 1 bi

+See More